LETTERS TO THE EDITOR
Cell Transformation Assays as Predictors of Carcinogenic Potential I refer to the abstract by LeBoeuf published in Toxicologic Pathology as part of the Current Issues section on alternative approaches for the assessment of carcinogenicity (1) . The role of transformation assays was discussed within the framework of problems associated with the current approach of using genotoxicity test batteries. Three problems were identified by LeBoeuf: (a) a high proportion of noncarcinogens yield a positive response in one or more of these tests, (b) nongenotoxic carcinogens are not detected, and (c) short-term in vivo assays with the desired sensitivity and specificity do not currently exist, making resolution of positive in vitro results problematic. A solution of these problems was suggested to lie with the use of the Salmonella assay in conjunction with a cell transformation assay, this battery providing &dquo;improved prediction of both genotoxic and nongenotoxic carcinogens relative to current genotoxicity batteries.&dquo; Data derived using the SHE cell transformation assay refined by LeBoeuf is used by LeBoeuf to justify these claims.
I am aware of the impressive database accrued by LeBoeuf for the SHE cell transformation assay via the Special Issue of Mutation Research recently devoted to this subject (2). My comments concern 2 implications of accepting the suggested improved predictivity of the Salmonella/SHE test battery. I accept the validity of the empirical data supporting LeBoeuf's position, but I have problems digesting 2 of the implications of that acceptance, as follows. Implication 1. About 25% of the National Toxicology Program (NTP) noncarcinogens (the best to consider) are mutagenic to Salmonella. If one adds the results of additional genetic toxicity assays to that figure, one can approach the &dquo;high proportion of noncarcinogens [that] yield a positive response in 1 or more of these tests&dquo; referred to by LeBoeuf. This observation probably hides 2 separate problems. First, the large majority of the &dquo;false-positive&dquo; responses of the Salmonella assay arise from chemicals that have features within their structure that lead one to accept the mutagenic effects seen. I have always accepted this as an inevitable reflection of the enhanced sensitivity of in vitro tests-part of their advantage, in fact. I have also always assumed that such oversensitivity reflects the functional absence of Phase II enzymes in the S9 mix employed with all in vitro assays, except the SHE assay, which relies on its own metabolic competence. This problem associated with the use of S9 mix necessitates the subsequent evaluation of in vitro mutagens for evidence of mutagenicity in vivo, in order to discern potentially significant mammalian mutagens. In contrast, some other mutagenicity assays generate positive responses for agents that historical precedents and chemical theory do not indicate should be mutagenic.
Sometimes, such instances teach one something new about the chemical basis of mutagenicity or the subtlety of mammalian metabolism. An example of the former being provided by etoposide and, of the latter, by tamoxifen. On other occasions, one tends to conclude that the assay in question is generally nonspecific. Distinguishing these 2 options can involve a significant amount of work, and often one relies on informed judgment alone. Thus, when LeBoeuf suggests that the SHE assay is much less prone to generate false-positive results (the 25% generated by the Salmonella assay is implicitly accepted with the 2-test battery), I ask why that should be, and I cannot find an answer. Perhaps the SHE assay has the perfect balance of enzymes encountered in the tissues of rodents, and thus it quenches false-positive responses, much as the whole animal is assumed to do in in vivo genetic toxicity assays. That solution is subject to the unlikely corollary that these embryonic cells are capable of simulating accurately the metabolic environment of the 35 tissues in which the NTP rodent carcinogens have been known to elicit tumors. An alternative idea is that the SHE cells are sensitive to some intrinsic carcinogenic potential of chemicals that is capable of being interrogated in vitro-the perfect &dquo;black box&dquo; predictor. That may be so, but it implies the need to suspend critical judgment of the assay, because nobody can legitimately question the performance of an assay that is operating by an unknown mechanism. These uncertainties pale in the light of the second implication of the proposed 2-test battery. Implication 2. The large majority of the carcinogens detected by the SHE assay, and not by the Salmonella assay, display a remarkable level of species/gender/tissue specificity; they are generally also regarded as putative nongenotoxic carcinogens. Herein, in fact, lies the main claimed attribute of the SHE assay. However, the fact that the nonmutagenic liver-specific rodent carcinogen diethylhexyl phthalate (DEHP) transforms SHE cells im-plies that some intrinsic carcinogenic property of DEHP is capable of being expressed in cultured SHE cells but not in the other 34 tissues evaluated in the NTP rodent carcinogenicity bioassay. Equally, this activity in SHE cells is automatically implied to be of greater mechanistic significance than the cascade of liver-associated events that are thought by many investigators to be implicated in the carcinogenicity of this chemical (activation of PPAR, induction of P-450, peroxisome proliferation, stimulation of cell division, suppression of apoptosis, etc.). Likewise, the SHE activity of a range of nonmutagenic thyroid-specific rodent carcinogens is implied to take precedence over the complex intact-mammal phenomena of thyroid-stimulating hormone (TSH)-mediated thyroid gland hyperplasia, again associated by many with the eventual induction of thyroid tumors by such agents.
The cut-off of these alternative mechanisms is absolute-SHE cells do not undergo peroxisome proliferation in the presence of DEHP leading to transformation, and they do not secrete TSH into the assay medium in the presence of thiourea. Similar arguments apply to the assay's ability to detect as positive a range of male rat kidney-specific carcinogens and so forth. These several examples pose the central question of how the SHE assay manages to anticipate so many exquisitely specific carcinogenic effects and the corollary question, of how so many alter-native mechanistic models, focused on the rodent tissues subject to carcinogenesis, can be so apparently irrelevant.
The proposals made by LeBoeuf are bold, and they have the potential to simplify dramatically the prediction of rodent carcinogens. However, the days of empirical correlations in carcinogen prediction have passed. Therefore, if the SHE assay is to be adopted for the purposes outlined by LeBoeuf, it will be necessary to rationalize the apparent success of the assay and to confirm that it can be conducted reproducibly in a range of laboratories, with each investigator applying common objective criteria for the recognition of a transformed colony. JOHN Toxicologic pathologists in industry have put a great deal of time and work into developing an unbiased pathology peer-review system that guarantees the integrity of the data in a cost-effective manner. The majority (certainly all of the larger pharmaceutical companies) already use pathology peer review (i.e., a second pathologist re-views selected tissues and either verifies or not the conclusions of the original pathologist), even without an FDA requirement to do so. The format and procedures of exactly how this is done may differ somewhat from company to company, but the important fact remains that 2 pathologists have agreed on the final conclusions of the study, that is, what the lesions and target tissues are and at what doses they occurred. Whether or not the 2 pathologists agreed on the specific diagnosis for a single tissue is not important, but whether they agreed on the final interpretation of the full study is. Dr. Peters' proposal seems to dwell on the opposite, with an emphasis on documentation of different diagnoses for individual tissues by the 2 pathologists. Most of these &dquo;differences&dquo; will turn out to be nonsubstantive and will not affect the overall conclusion of the pathology report. Dr Peters' highly detailed plan, which would be required of all companies submitting data from a &dquo;pivotal (usually chronic/
